OBJECTIVES We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH). METHODS: We used the Health Insurance Review and Assessment Service database from January 1st 2005 to June 30th 2006 for this study. The male patients with BPH and who had a prescription for alpha blockers following any fractures were defined as the cases. We set the 20 day long hazard period prior to the index date and the four control periods whose lengths were same with hazard period. After 1:4 matching of the hazard and control periods, conditional logistic regression was used to calculate the odds ratios for the risk of fractures as related to the alpha blocker exposure. RESULTS: Doxazosin and tamsulosin showed the increased risk of fractures, whereas terazosin did not. After stratification using the defined daily doses, a protective effect was shown for the patients who took terazosin at the doses lower than 0.4 DDD and the hazardous effect at the doses higher than or equal to 0.4 DDD. There was no significant difference for the risk of patients taking tamsulosin at the doses higher than 1.0 DDD but there was a statistically significant increase in the risk at the doses higher than or equal to 1.0 DDD. CONCLUSIONS: Alpha blockers for BPH may increase the risk of fracture in elderly patients who have comorbidities and take the concomitant medications. Alpha blockers need to be prescribed with caution, although some have high prostate specificity.
Summary
Citations
Citations to this article as recorded by
Risk for Hip Fracture due to Alpha Blocker Treatment in Korean Women: National Health Insurance Database Study Gi H. SEO, Sung R. SHIM, Hwan W. LEE, Jin H. KIM, Dong‐Il CHUN, Hyun J. KIM, Hyun Y. LEE, Jae H. KIM LUTS: Lower Urinary Tract Symptoms.2018; 10(2): 175. CrossRef
Risk of hip/femur fractures during the initiation period of α‐adrenoceptor blocker therapy among elderly males: a self‐controlled case series study Chao‐Lun Lai, Raymond Nien‐Chen Kuo, Ho‐Min Chen, Ming‐Fong Chen, Kinwei Arnold Chan, Mei‐Shu Lai British Journal of Clinical Pharmacology.2015; 80(5): 1208. CrossRef
The Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures Sian Yik Lim, Pavis Laengvejkal, Ragesh Panikkath, Kenneth Nugent The American Journal of the Medical Sciences.2014; 347(6): 463. CrossRef
Alpha-adrenergic blocker mediated osteoblastic stem cell differentiation Yoon Jung Choi, Jue Yeon Lee, Seung Jin Lee, Chong-Pyoung Chung, Yoon Jeong Park Biochemical and Biophysical Research Communications.2011; 416(3-4): 232. CrossRef
Risk of fractures associated with treatment for benign prostate hyperplasia in men P. Vestergaard, L. Rejnmark, L. Mosekilde Osteoporosis International.2011; 22(2): 731. CrossRef
Databases in Asia and Record-Linkage Kiyoshi KUBOTA Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku.2011; 16(1): 27. CrossRef
Air pollution epidemiologic studies are intrinsically difficult because the expected effect size at general environmental levels is small, exposure and misclassification of exposure are common, and exposure is not selective to a specific pollutant. In this review paper, epidemiologic study designs and analytic methods are described, and two nationwide projects on air pollution epidemiology are introduced. This paper also demonstrates that possible confounding issues in time-series analysis can be resolved and the impact on the use of data from ambient monitoring stations may not be critical. In this paper we provide a basic understanding of the types of air pollution epidemiologic study designs that be subdivided by the mode of air pollution effects on human health (acute or chronic). With the improvements in the area of air pollution epidemiologic studies, we should emphasize that elaborate models and statistical techniques cannot compensate for inadequate study design or poor data collection.